Logo

Glenn Miles

Nov 14, 2018

Cancer Genetics has appointed Glenn Miles as its chief financial officer, effective November 26, 2018. In addition, the company said that Igor Gitelman, its current chief accounting officer, will be departing.

Miles has more than 30 years' experience in a variety of accounting and finance roles and has been a full time contractor with Cancer Genetics since this July. Prior to joining Cancer Genetics, he served as President and CFO of management advisory firm Catalytic Consulting, was biopharma controller for Europe, Latin America and US oncology at Pfizer, and held various senior-level finance positions at Lehman Brothers and AT&T Mobility. He holds an MBA from Mercer University and bachelors in commerce and accounting from the University of Alabama.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.